Margins hit 24% target early; synergies front-loading ahead of schedule

₹2,829.2 Cr reported (136% YoY on reported basis, 19% on combined like-for-like basis post-Quality Care integration from July 1)

EBITDA ₹678 Cr / ₹2,829 Cr = 24% margin; delivered OPM 22.8% (EBIT, excluding D&A)

Embedded in consolidated profit; run-rate implies ₹200 Cr over 4 quarters, full realization by Q6-Q7 FY27

Prior: ₹150-200 Cr over unspecified horizon. Now: ₹16.6 Cr Q2 (₹65 Cr run-rate), full ₹200 Cr by Q6-Q7 FY27 (front-loaded from prior 3-year-plus expectation).

Prior: 24%-25% EBITDA margins by 2028-29 (2-3 years). Now: Already achieved 24% in Q2 FY27 (first full quarter post-merger).

4,230 additional beds in pipeline disclosed; targeting 15,000 total capacity (from 10,840 current). ₹1,200 Cr+ capex invested over 18 months.

₹16.6 Cr realized Q2 implies ₹65 Cr run-rate. Will hit full ₹200 Cr by Q4 FY27 on run-rate, full realization by Q6-Q7.

30% on articles via centralized buying (one entity vs. another). 10-point synergy wheel: material cost, F&B outsourcing, IT integration, talent sharing, clinical programs, indirect costs, etc.

Service delivery model less vulnerable than retail pharmacy. Private healthcare delivers 65% of India's care. India needs 1.5M beds over 10 years. Regulatory measures welcome for accessibility; cost to business limited.

Mature (64% beds, 73% revenue, 83% EBITDA): 3+ years, 25%+ margin. Focus: developing toward 25% (improving consistently). Underperforming: 11% beds, 5% revenue, small bucket with significant upside.

Greenfield in clusters; break-even timelines: Whitefield 3 months, Nagercoil 4, Kasaragod 9. Losses negligible, no P&L drag seen.

Not sharing separate metrics anymore. All 38 hospitals tracked as one network in monthly MIS; won't review separately.

CONGO (complex procedures) +16%, non-CONGO +19%. Seasonality: Q3-Q4 more festive (lower margins). Maintain 24%-25% target for 2-3 years post-merger.

~20% non-census, ~80%-81% census beds (rough ratio).

Three levers: (1) Efficiency (larger hospitals absorb costs better), (2) Segment growing well with clinical complexity (CONGO +16%, non-CONGO +19%), (3) Brownfield expansion with 2,000 beds added to mature segment. Margin expansion continues from CONGO growth and brownfield ramp-up.

Prior call: 5-8% ARPP growth + 5-6% volume growth assumed. This call focuses on combined network trajectory without discrete FY27 numbers.

Already achieved 24% in Q2 (first full quarter), ahead of 2028-29 timeline. Reaffirmed multiple times on call.

Q3-Q4 more festive (lower elective procedures); seasonal variation acknowledged but 24% target firm.

Targeting 4,230 additional beds (10,840 to 15,000 capacity). ₹1,200 Cr+ over 18 months implied. Timeline through FY27-FY28.

Merging Aster DM, CARE, KIMSHEALTH, Evercare requires harmonizing clinical practices, procurement, IT, talent. First 100 days completed; deeper integration ongoing.

Kerala assembly committee recommended comprehensive price controls on hospitals. Oncology drug price capping announced. Business model defended as service delivery (not retail), but regulatory uncertainty persists.

4,230 bed expansion pipeline across 18 months. Management cites break-even timelines (Whitefield 3M, Nagercoil 4M, Kasaragod 9M), but scale of expansion and market absorption risk remain.

Management claims ₹65 Cr run-rate by Q4 FY27 and full ₹200 Cr realization by Q6-Q7 FY27. Dependent on procurement integration, talent sharing, clinical standardization execution.

Expanding 4,230 beds in Tier 2/3 markets assumes market absorption and pricing discipline. Competitor capacity additions and regulatory scrutiny could compress margins.